Synonym: Behçet's syndrome
Behçet's disease is a complex multi-system disorder of unknown aetiology characteristically presenting with recurrent oral ulcers. It is presumed to be an autoimmune disease and includes involvement of the mucocutaneous, ocular, cardiovascular, renal, gastrointestinal, pulmonary, vascular, musculoskeletal, urological and central nervous systems. In many patients the activity of this disease diminishes with time.
The International Classification Criteria of Behçet's Disease are as follows:
- In the absence of other clinical explanations, patients must have recurrent oral ulceration (aphthous or herpetiform) observed by the physician or patient, recurring at least three times in a 12-month period, and two of the following:
- Recurrent genital ulceration.
- Eye lesions: anterior uveitis, posterior uveitis, cells in the vitreous by slit lamp examination or retinal vasculitis observed by an ophthalmologist.
- Skin lesions: erythema nodosum, pseudo-folliculitis, papulopustular lesions or acneiform nodules in post-adolescent patients not on corticosteroids.
- Pathergy (exaggerated skin injury occurring after minor trauma), read by a physician at 24-48 hours.
- This condition is not commonly seen in Northern Europeans. The prevalence is highest in the Middle East, Mediterranean and Eastern Asia.
- The prevalence is 80 to 370 cases per 100,000 population in Turkey, 10 per 100,000 in Japan and 0.6 per 100,000 in Yorkshire. European cases are more often described - but not exclusively - in the migrant population.
- HLA-B51 is the most strongly associated known genetic factor. However, it accounts for less than 20% of the genetic risk, even in familial cases (less than 5%), which indicates that other genetic factors remain to be discovered. It is most common among patients aged 20-30 years.
- An age of onset younger than 25 years is associated with a higher prevalence of eye disease and active clinical disease.
- Males and females are equally affected. However, males tend to have a more active and more severe form of the disease.
- Nonspecific symptoms include tiredness, malaise, muscle pains, and transient fevers. Headaches can be common.
- Although oral ulceration, genital ulceration and eye disease are the classic triad of manifestations, the cardiovascular, gastrointestinal, musculoskeletal and central nervous systems can also be affected.
- Skin and mucous membranes:
- Painful aphthous ulcers occur in any part of the moist mucosal surfaces inside the mouth. They do not occur actually on the lips. The ulcers may last for as long as three weeks.
- Skin lesions can occur in the genital regions. The ulcers are very painful. They do not usually occur on the penis.
- Painful nodules on the legs can occur due to erythema nodosum.
- Patients often present with acne-like lesions on the arms and/or legs.
- Eyes: about half of patients have uveitis. Other ocular manifestations include hypopyon, retinal vasculitis, retinal haemorrhage, blurred vision and photophobia.
- Neurological: central nervous system (CNS) involvement occurs late in the disease. Memory impairment is the most common CNS manifestation. Impairment of balance, speech and movement can also occur. Thrombosis within the dural venous sinuses may occur. Peripheral nerve involvement is rare.
- Vascular lesions include vasculitis of the small and large vessels, deep vein thrombosis and superficial thrombophlebitis, arterial occlusions and aneurysms.
- Cardiac lesions include arrhythmias, pericarditis, vasculitis of the coronary arteries, endomyocardial fibrosis, and granulomas in the endocardium.
- Arthritis: arthritis and arthralgias are common; a non-erosive arthritis occurs which most often affects the lower limbs, especially the knee. It can also affect the small joints. Back pain due to sacroiliitis may also occur.
- Gastrointestinal: cramping abdominal pain, vomiting, diarrhoea or, less commonly, gastrointestinal bleeding can occur. Ulcerative lesions may occur in any part of the gastrointestinal tract.
- Other manifestations include epididymitis, glomerulonephritis, lymphadenopathy, myositis and polychondritis. Amyloidosis may occur but is very uncommon.
- This depends on which systems are involved. Many other possible conditions usually need to be considered in view of the very variable presentation.
- Sarcoidosis, multiple sclerosis, Crohn's disease, Takayasu's arteritis, polychondritis or antiphospholipid syndrome need to be considered.
- Differential diagnosis of oral or genital ulcers includes herpes simplex, hand, foot and mouth disease, herpangina, histoplasmosis, inflammatory bowel disease, seronegative spondyloarthropathies, acne vulgaris and rheumatoid arthritis.
There is no relevant specific test for diagnosis. The ESR, CRP and other acute-phase reactants may be elevated during the acute phase and/or relapses but do not correlate with disease activity. Abnormalities of fibrinolysis, elevated factor VIII, immune circulating complexes and cryoglobulinaemia have been occasionally reported. Leukocytosis is frequently present. The positivity of HLA-B51 allele is of no diagnostic value. Cutaneous biopsy of intradermal injection with physiological saline solution may demonstrate vasculitis with immune complexes deposit.
Investigations are therefore not required to confirm the diagnosis but are required when considering possible differential diagnoses and to assess the presenting features that may be present:
- FBC may show mild anaemia and raised white cell count.
- Nonspecific inflammatory markers: CRP, ESR, complement and acute-phase reactants may all be elevated during an acute attack.
- Antiphospholipid antibodies are positive in 25% of patients.
- Pathergy test: minor skin trauma induces an inflammatory papule or pustule after 24-48 hours. This is positive in up to 60% of patients.
- Imaging studies, including CT and/or MRI scan, may be undertaken in some patients.
- Angiography is required to identify and assess aneurysms.
- Patients positive for HLA-B51 or HLA-B5 are more likely to be male and also have higher prevalences of genital ulcers, ocular manifestations and skin manifestations, and a decreased prevalence of gastrointestinal involvement.
The aim of treatment is to prevent long-term damage. The most severe manifestation present in the patient usually determines the choice of treatment.
- Local therapy:
- Topical corticosteroids (eg, triamcinolone paste) are effective for oral or genital ulcerations if they are applied during the prodromal stage of ulceration when the symptoms are more mild.
- Systemic manifestations:
- Lesions resistant to local measures may require systemic treatment.
- Systemic treatments are usually given for 1-2 years. They may be given longer for those with gastrointestinal involvement.
- Patients with eye involvement need early and more aggressive treatment, usually with a brief course of corticosteroid with a longer-term immunosuppressant (eg, azathioprine).
- Patients with CNS involvement require the most aggressive treatment, usually with a corticosteroid plus either azathioprine, cyclophosphamide, or a TNF-alpha inhibitor.
- Continual use of immunosuppressive medications may be required to suppress disease.
- Corticosteroids are effective for acute manifestations but there is no evidence of any beneficial effect on disease progression.
- TNF antagonists - eg, infliximab - can be effective.
- Mucocutaneous lesions and joint involvement:
- These may respond to non-steroidal anti-inflammatory drugs, prednisolone, levamisole, colchicine, dapsone, or sulfapyridine and thalidomide.
- In most patients, arthritis can be managed with colchicine. Local corticosteroid injections may also be used.
- Immunosuppressive therapy with azathioprine may be effective.
- Major vessel disease:
- Vasculitis is treated with immunosuppressive medication.
- Prevention of acute deep vein thrombosis is by using immunosuppressive agents rather than anticoagulants.
- If a venous thrombotic event does occur, however, warfarin is usually given.
- For pulmonary and peripheral arterial aneurysms, immunosuppressants and corticosteroids are usually given.
This may be required for:
- Gastrointestinal complications - eg, perforation and peritonitis.
- Aneurysms or ischaemic tissues affected by vasculitis or thrombosis.
- Ventricular aneurysms and coronary thrombosis.
- Eye involvement - eg, glaucoma, cataracts or retinal detachment.
- CNS aneurysms or clots.
- Vasculitis, rupture of aneurysms and thrombosis may all lead to potentially fatal cardiovascular complications.
- CNS involvement can lead to permanent deficits.
- Eye involvement may result in blindness.
- There is a very variable course of recurrences and remissions lasting for years.
- The majority of new manifestations occur within the first five years after onset of the disease.
- Prognosis will depend on which systems are involved. Men tend to have a poorer prognosis.
- Mortality is usually low but death may occur as a result of neurological involvement, vascular disease, bowel perforation, cardiopulmonary disease, or as a complication of immunosuppressive therapy.
- Although treatment of skin-mucosal manifestations, eye disease and pulmonary artery aneurysms has improved significantly in the past few decades, the treatment of CNS lesions is still problematic.
Further reading and references
; Behcet's disease. Orphanet J Rare Dis. 2012 Apr 127:20. doi: 10.1186/1750-1172-7-20.
; Treatment strategies for Behcet's disease. Expert Opin Pharmacother. 2008 Dec9(18):3211-9.
; Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol. 2012 Sep 25. doi: 10.1038/nrrheum.2012.156.
; Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009 Feb8(2):192-204.
; Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012 May51(5):887-900. Epub 2012 Jan 11.
; European League Against Rheumatism (January 2008)
; Mortality in Behcet's syndrome. Clin Exp Rheumatol. 2008 Sep-Oct26(5 Suppl 51):S138-40.
; Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007 Mar3(3):148-55.